Denali Therapeutics (DNLI) Current Assets (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Current Assets data on file, last reported at $1.0 billion in Q1 2026.

• Quarterly Current Assets rose 16.4% year-over-year to $1.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 billion (up 16.4% YoY) and the FY2025 annual result came in at $900.7 million, up 4.19% from the prior year.
• Current Assets rose to $1.0 billion in Q1 2026 per DNLI's latest filing, from $900.7 million in the prior quarter.
• Across five years, Current Assets topped out at $1.4 billion in Q4 2022 and bottomed at $864.4 million in Q4 2024.
• The 5-year median for Current Assets is $988.4 million (2022), against an average of $1.0 billion.
• Peak annual rise in Current Assets reached 52.95% in 2022, while the deepest fall reached 30.96% in 2022.
• Tracing DNLI's Current Assets over 5 years: stood at $1.4 billion in 2022, then retreated by 22.46% to $1.1 billion in 2023, then declined by 18.77% to $864.4 million in 2024, then gained by 4.19% to $900.7 million in 2025, then gained by 13.56% to $1.0 billion in 2026.
• Per Business Quant, the three latest DNLI Current Assets figures stand at $1.0 billion (Q1 2026), $900.7 million (Q4 2025), and $882.6 million (Q3 2025).

Peer Comparison